Daily Respiratory Research Analysis
Analyzed 108 papers and selected 3 impactful papers.
Summary
Top respiratory findings today: (1) A multicenter protocol defining age-specific tidal-breathing nasal NO cutoffs enables reliable adjunctive diagnosis of primary ciliary dyskinesia in infants and preschoolers. (2) An intranasal SARS-CoV-2 S-2P plus lentinan formulation confers broad, IFN-γ–dependent protection against variants in mice, advancing mucosal vaccine strategies. (3) An updated meta-analysis of RCTs shows stem cell therapies do not improve key outcomes in ARDS, underscoring the need for rigorous trials.
Research Themes
- Pediatric respiratory diagnostics and rare disease
- Mucosal vaccination and antiviral immunity
- Evidence synthesis guiding ARDS therapeutics
Selected Articles
1. Tidal Breathing Nasal Nitric Oxide Measurement as a Test for Primary Ciliary Dyskinesia in Young Children.
A standardized protocol for tidal-breathing nasal nitric oxide (nNO) with age-specific cutoffs was developed and validated across 8 sites. nNO values increased with age in healthy children but remained low in PCD, enabling high-sensitivity adjunctive diagnosis from as early as 2 months.
Impact: Addresses a critical diagnostic gap for infants and preschoolers who cannot perform velum-closure maneuvers, potentially expediting PCD diagnosis and reducing invasive testing.
Clinical Implications: Integrate tidal-breathing nNO with age-specific cutoffs as an adjunctive test in the PCD workup for children under 6, alongside genetics and ciliary ultrastructure, to accelerate diagnosis and care pathways.
Key Findings
- Developed a standardized tidal-breathing nNO protocol with age-specific cutoffs optimized at sensitivity 0.98.
- In healthy controls, nNO increased from birth to 6 years, while remaining low in children with PCD.
- Multicenter validation at eight sites (n=107 evaluated for PCD) supported diagnostic utility in young children.
Methodological Strengths
- Prospective development with multicenter external validation
- Standardized protocol and age-normative curves with statistical modeling (GEE)
Limitations
- Cutoffs tuned for high sensitivity may reduce specificity and require local calibration
- Detailed sample distribution across youngest age bands and disease phenotypes not fully detailed in abstract
Future Directions: Prospective diagnostic accuracy studies in broader, diverse cohorts with standardized reference standards; assess integration with genetics to build cost-effective diagnostic algorithms.
RATIONALE: Nasal nitric oxide (nNO) measurement during velum closure is a useful test for primary ciliary dyskinesia (PCD) but not feasible in young children. Measurement during tidal breathing is an alternative approach. OBJECTIVES: To define a protocol with age-specific cut-off values for nNO measurements during tidal breathing and evaluate as an adjunctive test for PCD. METHODS: A standardized method for nNO measurement during tidal breathing was developed and tested at University of North Carolina in children under 6-years with PCD, asthma, cystic fibrosis, and healty controls. Normative curves were generated as a function of age and generalized estimating equations were used to define age-specific cut-off values. The protocol was subsequently validated in 107 children undergoing evaluation for PCD at eight additional sites. RESULTS: In healthy controls, tidal breathing nNO values increased from birth to age 6-years, but remained low for children with PCD. With sensitivity set at 0.98, cut-off values of nNO increased from 13.9 nL·min
2. Intranasal S-2P and lentinan formulation confers broad protection against SARS-CoV-2 VOCs via IFN-γ-dominant mechanisms.
Intranasal S-2P acts as a self-adjuvanted antigen that elicits robust mucosal and systemic immunity via integrin/STING pathways. In mice, S-2P provided complete protection against ancestral SARS-CoV-2 and partial Omicron protection; co-formulation with lentinan achieved complete Omicron protection through IFN-γ–dominant, largely CD8-independent mechanisms.
Impact: Demonstrates a mechanistically defined mucosal vaccine strategy with broad variant coverage and a non–neutralizing antibody–centric protection mode, informing next-generation respiratory vaccines.
Clinical Implications: Preclinical data support advancing intranasal S-2P plus lentinan into early-phase clinical trials, with endpoints capturing mucosal immunity and IFN-γ–mediated protection across variants.
Key Findings
- Intranasal S-2P induces robust systemic and mucosal immunity via integrin- and STING-dependent pathways.
- S-2P confers complete protection against ancestral SARS-CoV-2 and partial protection against Omicron in mice, dependent on IFN-γ and CD8+ T cells.
- S-2P plus lentinan confers complete protection against Omicron variants through IFN-γ–dominant mechanisms, largely independent of CD8+ T cells.
Methodological Strengths
- Mechanistic dissection of pathways (integrin/STING, IFN-γ, CD8+ dependency) with in vivo challenge models
- Comparative antigen control (influenza HA) and safety signal (no VAERD) exploration
Limitations
- Preclinical murine data; no human immunogenicity or efficacy yet
- Durability of protection and manufacturability of the formulation require further study
Future Directions: Phase 1 trials assessing safety, mucosal IgA, IFN-γ responses, and controlled human infection or real-world effectiveness; formulation optimization and stability studies.
Effective respiratory mucosal vaccines remain urgently needed to mitigate the rapid mutation and transmission of SARS-CoV-2. Here, we demonstrated that the spike protein (S-2P) of ancestral SARS-CoV-2 acted as a self-adjuvanted antigen for intranasal immunization, inducing robust systemic and mucosal immunity via integrin- and STING-dependent pathways. In contrast, H1N1 influenza hemagglutinin (HA) failed to generate measurable serum IgG or mucosal IgA following intranasal immunization. In mice, intranasal S-2P vaccination conferred complete protection against lethal ancestral SARS-CoV-2 challenge and partial cross-protection against heterologous Omicron variants, with both effects being IFN-γ- and CD8 + T cell-dependent. Co-administration of S-2P with the clinical immunomodulator lentinan (LNT) achieved complete protection against Omicron variants, mediated by IFN-γ but largely independent of CD8 + T cells. These findings establish S-2P + LNT as a safe, broad-spectrum mucosal vaccine candidate against emerging SARS-CoV-2 variants and reveal novel protection mechanisms beyond neutralizing antibodies and T cell immunity.
3. Efficacy and safety of stem cell therapy vs. standard of care in patients diagnosed with acute respiratory distress syndrome: an updated systematic review and meta-analysis of randomized controlled trials.
Across 17 randomized trials, stem cell therapies did not significantly reduce 28-day mortality or serious adverse events compared with standard care in ARDS. The certainty of evidence was low to very low by GRADE, highlighting persistent methodological and heterogeneity challenges.
Impact: Provides a rigorous synthesis countering therapeutic optimism around stem cell therapy in ARDS and informs clinicians and guideline committees to limit use to trials.
Clinical Implications: Stem cell therapies should not be used routinely for ARDS outside clinical trials; focus should remain on evidence-based supportive care and enrollment in high-quality RCTs.
Key Findings
- Seventeen RCTs were included after screening 5,537 records.
- No significant reduction in 28-day mortality with stem cell therapy versus standard care (RR 0.809, 95% CI 0.651–1.005).
- Certainty of evidence rated low to very low by GRADE; serious adverse events showed no clear improvement.
Methodological Strengths
- PROSPERO-registered protocol with comprehensive multi-database search
- Use of GRADE to appraise certainty and standardized meta-analytic methods
Limitations
- Heterogeneity across stem cell types, dosing, and timing limits pooled precision
- Low to very low certainty reflects small, heterogeneous trials and risk of bias
Future Directions: If pursued, trials should be large, preregistered, mechanistically stratified (e.g., ARDS endotypes), and report standardized outcomes to clarify any niche benefits.
OBJECTIVES: This systematic review and meta-analysis aimed to evaluate the efficacy and safety of stem cell therapies as compared to the standard of care (SOC) in patients with acute respiratory distress syndrome (ARDS). METHODS: Search of PubMed, Embase, Cochrane CENTRAL, and Web of Science databases for randomized controlled trials was performed. The protocol was registered in PROSPERO (ID: CRD42023467612). The primary outcomes were all-cause mortality on day 28 and serious adverse events. Risk ratios (RR) and mean differences were pooled using Stata software version 17.0. Quality of the evidence was assessed by GRADE approach. RESULTS: Out of 5,537 articles screened, 17 were included. Treatment with stem cells led to no significant difference in the risk of 28-day mortality [RR, 0.809 (95% CI: 0.651-1.005), CONCLUSION: There was no significant improvement in critical outcomes following stem cell therapy as compared to the SOC in ARDS. The certainty of evidence was low to very low, indicating limited confidence in the findings. SYSTEMATIC TRIAL REGISTRATION: PROSPERO (ID: CRD42023467612).